TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer
Annals of Oncology - United Kingdom
doi 10.1016/j.annonc.2020.01.013
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2020
Authors
Publisher
Elsevier BV